Ecog smoldering myeloma trial

Author: srpq

August undefined, 2024

WebFeb 19, 2024 · ECOG performance status is scored on a scale from 0 to 5, with 0 indicating no symptoms and higher scores indicating increasing disability. ... Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood. 2024; 136 (8): 936-945. Google Scholar. … WebEAA173 or DETER-SMM is a randomized phase 3 trial for patients with smoldering multiple myeloma (SMM) and high-risk features. The usual course of action for patients … The ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) is a membership-based … Trial Monitoring – Group-wide Org Chart – Members – Find a Participating … Group-wide meetings of the ECOG-ACRIN Cancer Research Group (ECOG …

Clinical Controversies in the Management of Smoldering Multiple Myeloma ...

WebStudy Description. Single-cell RNA-sequencing identifies immune biomarkers of response to immunotherapy in patients with high-risk Smoldering Multiple Myeloma (SMM). We conducted a Phase II trial of the immunotherapeutic anti-SLAMF7 antibody, Elotuzumab, in combination with Lenalidomide and Dexamethasone (E-PRISM study), to determine the ... thierry aubier

Risk-benefit relationships in cancer clinical trials: the ECOG

WebIntroduction. Plasma cell myeloma is a clonal disorder of malignant plasma cells and is a disease of the elderly, with a median age of onset of 70 years. 1,2 Development of newer therapeutic agents over the last decade has led to improvements in survival in younger patients; 3,4 however, such benefits have yet to be realized in the very elderly (>80 … WebNov 13, 2024 · Both Spanish Myeloma and ECOG Groups have demonstrated that pts at high risk of progression to active MM benefit from early treatment with R-based regimens. Our next step was to design this phase 2, single arm trial, focusing on the same population, but with the potential goal of cure, defined by sustained minimal residual disease … WebJul 26, 2010 · This randomized phase II/III trial studies how well lenalidomide works and compares it to observation in treating patients with asymptomatic high-risk asymptomatic (smoldering) multiple myeloma. Biological therapies such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. sainsbury\u0027s bank official site

Understanding ASCENT Clinical Trial for High Risk Smoldering Myeloma ...

Treatment of older adult or frail patients with multiple myeloma

WebSmoldering multiple myeloma (SMM) is a precursor disease state that precedes the development of symptomatic myeloma. As we have learned more about the disease … WebSep 5, 2024 · An ongoing ECOG randomized trial is testing whether a standard myeloma therapeutic triplet (DRd) will be superior to prophylactic doublet therapy with lenalidomide … sainsbury\u0027s bank nectar cardWebJan 24, 2024 · The purpose of this study is to determine the efficacy of treating patients with intermediate risk smoldering multiple myeloma (SMM) with combinational therapy with … thierry aubrun

"WebApr 6, 2012 · These cells help produce antibodies and fight infection. Smoldering multiple myeloma (SMM) is a related condition that may develop into multiple myeloma. The … " - Ecog smoldering myeloma trial

Ecog smoldering myeloma trial

Treatment of older adult or frail patients with multiple myeloma

WebJan 24, 2024 · MGUS or low-risk smoldering myeloma. Diagnosed or treated for another malignancy ≤ 2 years before trial enrollment or previously diagnosed with another malignancy and have any evidence of residual disease. NOTE: Subjects with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone … WebPatients must be diagnosed with asymptomatic high-risk smoldering multiple myeloma (SMM) within the past 12 months. High-risk is defined by any one of the following factors: Abnormal serum free light chain ratio (=< 0.125 or >= 8.0 and involved chain < 100 mg/L) by serum free light chain (FLC) assay. Presence of t (4;14) or del 17p or 1q gain ...

Did you know?

WebIn this randomized, open-label, phase 3 trial, we randomly assigned 119 patients with high-risk smoldering myeloma to treatment or … WebOct 31, 2024 · The recent publication of the ECOG trial evaluating lenalidomide (Revlimid) treatment versus observation for patients with smoldering myeloma has prompted considerable discussion about the …

WebJul 26, 2016 · High-risk smoldering myeloma has been recognized as the optimal phase to test early treatment strategies. The upcoming ASCENT trial aims to prevent progression to active myeloma by 30% to 50% in the high risk to progression smoldering patients. We are talking to Dr. Shaji Kumar, Principal Investigator of the trial and Mayo Clinic expert, about ... WebPATIENTS WITH ASYMPTOMATIC HIGH-RISK SMOLDERING MULTIPLE MYELOMA Coordinating Group: ECOG Chairperson(s): Dr. Sagar Lonial ... the randomized portion of the trial will begin. 2. Mobilize stem cells following 4-6 cycles of therapy. While stem cell collection following 4-6 cycles of therapy is suggested strongly, it is not required for …

WebMar 31, 2024 · The first major trial to assess intervention in smoldering myeloma was performed by the PETHEMA group. 20 A treatment arm of lenalidomide and dexamethasone was compared with observation alone in a cohort of patients considered to be at high risk of progression to myeloma. Not only did the study reveal a 2-year progression-free survival … WebNov 11, 2024 · They should be used only in patients with symptomatic, overt MM; they should not be used in patients with smoldering myeloma or monoclonal gammopathy of undetermined significance, since their value in such populations is not known. ... Eastern Cooperative Oncology Group (ECOG) myeloma trial E9486 report by the ECOG …

WebActive Clinical Trials: Resources. Numerous clinical trials are always open and enrolling patients in the ECOG-ACRIN Cancer Research Group, which focuses its research on adults 18 years of age and older who have or are at risk of developing cancer. The table below contains a list of all active clinical trials, with links to the educational and ...

WebFeb 1, 2024 · The Spanish Myeloma Group and ECOG trials addressed the question of whether preventive therapy can delay progression to multiple myeloma and prevent end-organ damage . Trials are examining whether early therapy can potentially cure some patients with smouldering multiple myeloma (GEM-CESAR [NCT02415413] and … sainsbury\u0027s bank online portalWebFeb 1, 2024 · The Spanish Myeloma Group and ECOG trials addressed the question of whether preventive therapy can delay progression to multiple myeloma and prevent end … thierry aucouturierWebTesting the Use of Combination Therapy in Adult Patients with Newly Diagnosed Multiple Myeloma, the EQUATE Trial. ... (ECOG) performance status (PS) of 0-2 (PS 3 allowed … thierry aucouturier toulouse